Pancreatic cancer; Pathogenic mutation of the BRCA1 gene
Main Article Content
Abstract
Pancreatic cancer, although rare, ranks seventh in terms of cancer-related mortality, with a low five-year survival rate after diagnosis. Globally, it accounts for approximately 1.6-1.2% of cancer cases. In Mexico, it is also a significant cause of mortality, ranking sixth or seventh.
This type of cancer tends to occur more frequently in individuals over the age of 71, but there has been a marked increase in its incidence among younger patients. One of the most common risk factors is a family history of the disease, and a close relationship has often been noted between pancreatic cancer and newly diagnosed diabetes mellitus.
The primary objective of this study is to understand pancreatic cancer prevention in patients carrying the pathogenic mutation of the BRCA1 gene and explore innovative therapies. Both the BRCA1 and BRCA2 genes have been associated with various cancer types, such as breast, ovarian, and pancreatic cancer. In the case of the latter, it is believed that these genes may contribute to cancer by causing DNA damage.
The diagnosis of pancreatic cancer is based on imaging studies and biopsies. Furthermore, various treatment options are examined, including neoadjuvant therapies and potential therapeutic approaches.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Kim SH, Hwang HK, Lee WJ, Kang CM. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers. Pancreatology. 2021 Apr;21(3):544-549. doi: 10.1016/j.pan.2021.02.007. Epub 2021 Feb 14. PMID: 33612442.
II. Marina Macchini, Federico Centonze, Umberto Peretti, Giulia Orsi, Anna Maria Militello, Maria Maddalena Valente, Stefano Cascinu, Michele Reni, Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants, Cancer Treatment Reviews, Volume 100, 2021, 102262, ISSN 0305-7372.
III. Sawhney MS, Calderwood AH, Thosani NC, Rebbeck TR, Wani S, Canto MI, Fishman DS, Golan T, Hidalgo M, Kwon RS, Riegert-Johnson DL, Sahani DV, Stoffel EM, Vollmer CM Jr, Qumseya BJ; Prepared by: ASGE STANDARDS OF PRACTICE COMMITTEE. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. Gastrointest Endosc. 2022 May;95(5):817-826. doi: 10.1016/j.gie.2021.12.001. Epub 2022 Feb 16. PMID: 35183358.
IV. Afghani E, Klein AP. Pancreatic Adenocarcinoma: Trends in Epidemiology, Risk Factors, and Outcomes. Hematol Oncol Clin North Am. 2022 Oct;36(5):879-895. doi: 10.1016/j.hoc.2022.07.002. Epub 2022 Sep 23. PMID: 36154788.
V. Ayuso, C., Sánchez, M., Ayuso, J. R., De Caralt, T. M., & De Juan, C. (2019). Diagnóstico y estadificación del carcinoma de páncreas (I). Radiología. https://doi.org/10.1016/s0033-8338(06)75136-0
VI. Mizukami, K., Iwasaki, Y., Kawakami, E., Hirata, M., Kamatani, Y., Matsuda, K., Endo, M., Sugano, K., Yoshida, T., Murakami, Y., Nakagawa, H., Spurdle, A. B., & Momozawa, Y. (2020). Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes. EBioMedicine, 60, 103033. https://doi.org/10.1016/j.ebiom.2020.103033
VII. Golan, T., Kanji, Z., Epelbaum, R. et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111, 1132–1138 (2014). https://doi.org/10.1038/bjc.2014.418
VIII. Omar González-Santiago1*, Myrna L Yeverino-Gutiérrez1 , Ma del Rosario GonzálezGonzález1 , Ruth Corral-Symes1 , Pilar C Morales-San-Claudio. Evaluación de la mortalidad por cáncer de páncreas en México durante el periodo de 2000 – 2014.(2017).https://ecancer.org/es/journal/article/788-mortality-assessment-of-patients-with-pancreatic-cancer-in-mexico-2000-2014/pdf/es#:~:text=En%20este%20estudio%20se%20analiz%C3%B3,en%20las%20mujeres(9).
IX. Li, D. (2012). Diabetes and pancreatic cancer. Molecular Carcinogenesis, 51(1), 64–74. https://doi.org/10.1002/mc.20771